ARIA
Library/regeneration/BPC-157

BPC-157

Not FDA Approved✓ WADA Permitted

Body Protection Compound-157 / Gastric Pentadecapeptide

regeneration◆EmergingGastric pentadecapeptide

15-AA synthetic peptide from human gastric juice protein. Strongest preclinical evidence for tissue healing: muscle, tendon, ligament, bone, gut, neuro. No RCTs yet.

Confidence
62%
Half-Life ~4 hours (estimated)
Cost ~$300/mo
Quick Reference
Routesubcutaneous
MechanismVEGF upregulation → angiogenesis. NO pathway modulation. Enhanced fibroblast act...
SequenceGEPPPGKPADDAGLV
Mol. Weight1419.5 Da
Reviewed2026-07-08

Mechanism of Action

VEGF upregulation → angiogenesis. NO pathway modulation. Enhanced fibroblast activity and collagen synthesis. Reduces TNF-α, IL-6. Promotes F-actin formation. Neuroprotective via dopaminergic/serotonergic systems. Accelerates NGF/VEGF expression.

Dosing Protocol

200-500μg SC daily or BID near injury. Oral forms also used. Typical: 4-12 week cycles.

Key Studies

2026

BPC-157: Regeneration to Analgesia review

PMID 41898733systematic_review
2026

Injectable peptide therapy primer

PMID 41476424narrative_review
2014

BPC-157 tendon healing rats

PMID 25257670preclinical

Adverse Effects

Limited human dataTheoretical: dizzinessInjection site reactionsNo major AEs in limited studies

Contraindications

  • Limited human safety data
  • Active malignancy (theoretical: angiogenesis)
  • Pregnancy (insufficient data)

Storage

Lyophilized powder: room temperature. Reconstituted: refrigerate 2-8°C, use within 30 days.

Clinical Applications

  • ["post_surgical_recovery"
  • "tendon_ligament_repair"
  • "muscle_healing"
  • "wound_healing"]